QUANTUM BIOPHARMA-B SUB VOT (QNTM) Stock Price & Overview

NASDAQ:QNTM • CA74764Y2050

Current stock price

3.98 USD
-0.43 (-9.75%)
At close:
3.96 USD
-0.02 (-0.5%)
After Hours:

The current stock price of QNTM is 3.98 USD. Today QNTM is down by -9.75%. In the past month the price increased by 10.86%. In the past year, price decreased by -43.71%.

QNTM Key Statistics

52-Week Range2.07 - 38.25
Current QNTM stock price positioned within its 52-week range.
1-Month Range2.07 - 6.47
Current QNTM stock price positioned within its 1-month range.
Market Cap
15.283M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-10.32
Dividend Yield
N/A

QNTM Stock Performance

Today
-9.75%
1 Week
+3.92%
1 Month
+10.86%
3 Months
-43.22%
Longer-term
6 Months -78.43%
1 Year -43.71%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

QNTM Stock Chart

QUANTUM BIOPHARMA-B SUB VOT / QNTM Daily stock chart

QNTM Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to QNTM. When comparing the yearly performance of all stocks, QNTM is a bad performer in the overall market: 93.6% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QNTM Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to QNTM. QNTM may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QNTM Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.71
Revenue Reported
EPS Surprise %
Revenue Surprise %

QNTM Forecast & Estimates

7 analysts have analysed QNTM and the average price target is 31.01 USD. This implies a price increase of 679.12% is expected in the next year compared to the current price of 3.98.


Analysts
Analysts82.86
Price Target31.01 (679.15%)
EPS Next YN/A
Revenue Next YearN/A

QNTM Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

QNTM Financial Highlights

Over the last trailing twelve months QNTM reported a non-GAAP Earnings per Share(EPS) of -10.32. The EPS increased by 21.06% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-27.89M
Industry RankSector Rank
PM (TTM) N/A
ROA -197.07%
ROE -322.38%
Debt/Equity 0.28
Chartmill High Growth Momentum
EPS Q2Q%68.01%
Sales Q2Q%N/A
EPS 1Y (TTM)21.06%
Revenue 1Y (TTM)N/A

QNTM Ownership

Ownership
Inst Owners14.33%
Shares3.84M
Float3.50M
Ins Owners6.13%
Short Float %6.55%
Short Ratio0.74

About QNTM

Company Profile

QNTM logo image Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Company Info

IPO: 2018-05-29

QUANTUM BIOPHARMA-B SUB VOT

55 University Ave. , Suite 1003

TORONTO ONTARIO CA

Employees: 10

QNTM Company Website

QNTM Investor Relations

Phone: 14168548884

QUANTUM BIOPHARMA-B SUB VOT / QNTM FAQ

Can you describe the business of QUANTUM BIOPHARMA-B SUB VOT?

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


Can you provide the latest stock price for QUANTUM BIOPHARMA-B SUB VOT?

The current stock price of QNTM is 3.98 USD. The price decreased by -9.75% in the last trading session.


Does QUANTUM BIOPHARMA-B SUB VOT pay dividends?

QNTM does not pay a dividend.


What is the ChartMill rating of QUANTUM BIOPHARMA-B SUB VOT stock?

QNTM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Where is QUANTUM BIOPHARMA-B SUB VOT (QNTM) stock traded?

QNTM stock is listed on the Nasdaq exchange.


How is the valuation of QUANTUM BIOPHARMA-B SUB VOT (QNTM) based on its PE ratio?

QUANTUM BIOPHARMA-B SUB VOT (QNTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.32).


Would investing in QUANTUM BIOPHARMA-B SUB VOT be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QNTM.